Buoyed by PARP data and B-MS deal, Clovis CEO hunts for exciting pipeline candidates

10 September 2017

While it’s not unheard of to find a biotech firm in the American Mountain States, it is unusual.

In the case of Clovis Oncology (Nasdaq: CLVS), the explanation for its location in Colorado is clear, as co-founder and chief executive Pat Mahaffy explains: “I started the firm, and I live there.”

"There are advantages,” he says, “because people want to come to Boulder for the phenomenal lifestyle that it affords, so we can attract talent. But we also have an equally-sized office in San Francisco."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK